final program.qxd - Parallels Plesk Panel

OP 10.3
Current Advances in HIV Vaccine Development
Patricia D'Souza, NIAID, NIH, USA
Approximately 40 million people worldwide are living with HIV/AIDS. In 2005, an estimated
5 million people worldwide were newly infected with HIV. Although an HIV vaccine
remains the best hope for preventing new infections, it must be viewed as part of a multipronged
approach that complements other prevention and treatment strategies to decrease
HIV-1 transmission. An ideal vaccine should induce both cellular immunity and broadly
reactive neutralizing antibodies. Recent scientific advances which have aided HIV-1
vaccine development include an improved understanding that mucosal tissues are major
sites for early viral replication as well as an increased understanding of HIV envelope
structure. On the clinical front HIV vaccine pipeline is stoked with innovative vector-based
vaccine strategies that encompass multi-genes from multi-clades. Vaccine trials are being
conducted in a global network using validated laboratory measurements that enable
simultaneous measurement of multiple T cell vaccine-induced immune responses in
humans. Two vaccine strategies that successfully elicit HIV-1 CTL in humans use replication-incompetent
adenovirus vectors with or without recombinant DNA priming are
ongoing or close to starting in Phase II "test of concept" trials. Ultimately, the availability
of an effective HIV vaccine will require the cooperation and collaboration of the global
community to address key scientific roadblocks, manufacture clinical grade vaccines and
expand clinical trials capacity.
OP 10.4
Updated data on DermaVir
No abstract available
“ Focusing FIRST on PEOPLE “ 82 w w w . i s h e i d . c o m